Track 1: | Introduction |
Track 2: | Overview of PARP Inhibitors — Biologic Rationale and Mechanism of Action |
Track 3: | Side Effects and Toxicities of PARP Inhibitors |
Track 4: | PARP Inhibitors for Ovarian Cancer |
Track 5: | PARP Inhibitors for Breast Cancer |
Track 6: | PARP Inhibitors for Pancreatic Cancer |
Track 7: | PARP Inhibitors for Prostate Cancer |
FACULTY |
Emmanuel S Antonarakis, MD Professor of Oncology and Urology Johns Hopkins University The Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland |
Gretchen Santos Fulgencio, MSN, FNP-BC University of California, San Francisco Berkeley, California |
Kathleen Moore, MD The Virginia Kerley Cade Endowed Chair in Cancer Development Associate Director Clinical Research Director, Oklahoma TSET Phase I Program Stephenson Cancer Center Associate Professor Section of Gynecologic Oncology Director, Gynecologic Oncology Fellowship Department of Obstetrics and Gynecology University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma |
Joyce O’Shaughnessy, MD Celebrating Women Chair in Breast Cancer Research Baylor University Medical Center Director Breast Cancer Research Program Texas Oncology US Oncology Dallas, Texas |
Michael J Pishvaian, MD, PhD Associate Professor Department of Oncology Director of the Gastrointestinal Developmental Therapeutics and Clinical Research Programs at the NCR Kimmel Cancer Center at Sibley Memorial Hospital Johns Hopkins University School of Medicine Washington, DC |
Deborah Wright, MSN, APRN, CNS Phase I Clinical Nurse Specialist Oncology Infusion APP Team Lead Stephenson Cancer Center University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma |
MODERATOR |
Neil Love, MD Research To Practice Miami, Florida |